"In my opinion", Hippocrates starts his book on Prognostics, "it is highly necessary that a physician should bestow the utmost pains in attaining a foreknowledge of events, for when, with the sick, he perceives beforehand, and evinces a clear conception of the past, present, and future, discovering at the same time the neglects which they have committed, a higher degree of credit will be paid to his knowledge of their situation: so that mankind will, with greater confidence, commit themselves to his care. The cure will be better performed from a foreknowledge; but it is not possible that all the sick should be restored to a state of health, as the power of effecting this would indeed far surpass any anticipation of consequences." 1 Thus did the father of Modern Medicine lay the foundation of the art of prognostication in medicine. It is a necessary skill for a physician, but also one with uncertainties attached to its outcomes. However, according to Christakis, it is a skill that has been omitted from modern medical thought due to the emergence of effective therapies and a fundamental shift in the conceptualisation of disease in terms of diagnoses rather than with reference to patients. 2 He added that prognosis became implicit in diagnosis and treatment, thus losing its explicit identity. Glare and Sinclair demonstrated quantitatively the subservience of 'prognosis' to 'diagnosis' and 'therapy' by measuring the number of hits in a PubMed search; the number of hits for prognosis was eight to nine times less than those for the other two terms. 3 To an extent, the disappearance of 'prognosis' could be ascribed to the fact that the term is mostly associated with an answer to the question "Doc, how much time do I have?", 4 a question only one in three physicians discusses with their patients 5 -and avoided because physicians find themselves ill-prepared for prognostication and find it stressful to make predictions. 6 This digression into the 'lost art in Medicine' 7 is prompted by the paper by Lee et al. in this issue of the PCRJ, which compares rules for predicting the severity of hospitalised nursing home-acquired pneumonia in Korea. 8 Pneumonia is on the top of the list of causes of death in older ages and demands considerable attention from healthcare professionals, especially as their resources become limited. In response to constraints, the care setting for pneumonia has changed; this in turn is reflected in the varieties of pneumonia which have been described, resulting in a veritable 'alphabet soup': CAP, HAP, HCAP, NHAP, and VAP. 9 Community-acquired pneumonia (CAP) is distinct from other nosocomial forms of pneumonia like hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). 10 However, it is used as a catch-all classification for pneumonia acquired in non-hospital settings even when they are associated with health care. In 2005, the American Thoracic Society/Infectious Disease Society Guidelines designated pneumonia acquired in health care settings (like nursing homes and long-term care facilities) as health care-associated pneumonia (HCAP).
11 A sub-group of HCAP was further distinguished as nursing home-acquired pneumonia (NHAP).
The uses of a prediction tool in pneumonia include informing the physician about the management of the patient in terms of 'when', 'where' and 'how' -and, less commonly, informing the patient and/or family about the likely outcome. There are more such tools for CAP than NHAP, which would have been one of the motivations for Lee et al. to embark on their study. They pitted an NHAP-specific model against the Pneumonia Severity Index (PSI), SOAR (systolic blood pressure, oxygenation, age, and respiratory rate) and CURB-65 (confusion, urea nitrogen, respiratory rate, blood pressure, and age >65), and found that PSI had the greatest power of discrimination in predicting 30-day all cause mortality.
Interestingly, in the original study where it was introduced, PSI did not predict mortality and was proposed as a prediction rule to identify low risk patients. 12 In Lee et al.'s paper, PSI had a sensitivity of 78.3 and a specificity of 66.7, both below the 80 mark usually suggested as desirable for both sensitivity and specificity. Given such uncertainties, should such a mechanistic prediction rule guide the physician and supplant the art of prognostication with a machine? Although no head-to-head comparison between human and statistical prediction in respiratory diseases has been done, in mental health this has been a hotly discussed topic since 1954, when Paul Meehl, a Psychology professor, published his book comparing clinical versus statistical prediction. 13 Meehl presented 20 studies, the oldest from 1928, where clinical and statistical predictions were compared, and demonstrated the superiority of statistical prediction -much to the consternation of the profession. More recent reviews, using meta-analytical techniques, have continued to confirm these initial findings. Meehl 
EDITORIALS Editorial
Once-daily treatments are sometimes perceived to be the 'holy grail' in terms of promoting adherence. The idea that a simple once a day administration regime will foster adherence is certainly beguiling, but the research evidence is more nuanced. A number of systematic reviews 1, 2 and a recent meta-analysis 3 have addressed the relationship between adherence and dose frequency, and their findings do indeed suggest an inverse gradient between dose frequency and adherence. The meta-analysis by Coleman and colleagues 3 was methodologically more advanced and focused on oral dosage forms where adherence was assessed by electronic monitoring. The overall finding was that patients with long-term conditions (including three studies of patients with asthma) are more adherent to once-daily oral regimes than more frequent dosingand adherence was significantly higher for once-versus twice-daily regimes. This contrasts with the Claxton 1 and Saini 2 reviews which found that once-daily treatment was associated with significantly higher adherence than treatment three or four times a day, but found no significant differences between once-and twice-daily regimes overall.
However, we should be cautious about extrapolating these findings to a prescription of once-daily maintenance therapy for all patients with asthma and COPD. Although the aforementioned reviews [1] [2] [3] are well designed, they are inevitably limited by the fact that they draw on heterogeneous studies. Moreover, differences in adherence between once-versus twice-daily regimes, although statistically significant in the Coleman review, 3 were relatively small; the percentage of doses taken was 93.0% (95% CI 91.2 to 94.7%) versus 85.6% (95% CI 82.5 to 88.8%), respectively. These findings are similar to those obtained by Price and colleagues in their 12-week open-label study of 1,233 patients with asthma randomised to receive once-daily versus twice-daily dosing of mometasone fumarate administered by dry powder inhaler; 4 adherence was significantly higher with once-daily dosing, but adherence was high across the study and the difference between the dosing regimens was small (93.3% vs. 89.5%) -indicating that twice-daily dosing was not a significant barrier for most patients in the study. Nevertheless, research to date seems to be consistent with the 2008 UK National Institute for Health and Clinical Excellence (NICE) Medicines Adherence Guidelines Is once enough? Understanding the preferences of COPD and asthma patients for once-versus twice-daily treatment
